Clinical Trial

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07 -> 2028-07 2026-08-07
minor Completion pushed: 2027-07 -> 2030-07 2026-08-07
Trial Details
NCT Number NCT05990465
Lead Sponsor Medical College of Wisconsin
Conditions Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma
Enrollment 12 participants
Start Date 2025-02-06
Primary Completion 2028-07 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-06